State of the art MR-imaging in dementia: How AI and innovation can support differential diagnosis
Dementia is a debilitating disease that has touched many of our lives. In 2018, an estimated 9.1 Million people were living with dementia in EU member states with this number expected to rise by about 60% over the next two decades to reach 14.3 million in 2040.1
In this webinar we discuss the role of MR imaging in dementia and how emerging AI technologies can support differential diagnosis and provide invaluable information for disease management.
With new disease modifying treatments on the horizon this could bring significant improvements in quality of life for patients and their families alike.
- 18:00 – 17:05
Dr. Alessandro Roncacci, Senior Vice President Affidea - Introduction
- 18:05 – 18:30
Dr. Maria Politi - "The Role of Neuroimaging in Dementia"
- A systematic approach for MRI in Dementia
- Typical imaging findings in the most common dementia syndromes
- An overview of neurodegenerative disorders which may be associated with dementia.
- 18:30 – 18:55
Dr. Melissa Verheijen - "The use of MRI quantification in the differential diagnosis of dementia"
- MRI in dementia & Alzheimer’s Disease
- Normal ageing vs pathological ageing
- How can we extract more information from MRIs to reduce the time to diagnosis?
- Automated quantitative analysis to detect & diagnose
- The future: MRI to monitor Disease Modifying Therapies for Alzheimer’s Disease
- 18:55 – 19:00
Dr Maria Politi
Dr Maria Politi is Affidea’s Neuroimaging Subspecialty Expert. She has a wealth of experience as a co-investigator in clinical trials in the field of stroke medicine with over 50 publications, more than 700 citations and numerous lectures. She also participated in writing the Clinical recommendations for Mechanical Thrombectomy in Patients with Acute Stroke for the Hellenic Stroke Organisation.
Dr Politi graduated from the Medical School of Thessaly University (2001) and trained as a Radiologist and Neuroradiologist at University Hospital of Saarland, Germany (2010). She was trained on Neuroimaging as a clinical Research Fellow at the German Cancer Center at University of Heidelberg, Germany (2005-2006). She received her PhD in fMRI with the thesis “Brain plasticity in patients with complete achromatopsia” from the University of Saarland (2014), degree “summa cum laute”, and achieved subspecialty status as a Diagnostic and Interventional radiologist in Germany.
From 2012 until 2018, Maria served as a Consultant in the department of Diagnostic and Interventional Neuroradiology in Bremen, Germany. In 2018 she took up a role at the Henry Dunant Hospital in Athens for endovascular treatments and was appointed Head of Neuroimaging in Affidea Greece in 2019.
Dr. Melissa Verheijen
Dr. Melissa Verheijen attended University College London from 2015-2019, where she received her PhD in Immunology, and developed a desire to improve patient healthcare. She subsequently went on to become a clinical expert for icometrix, a company that leverages artificial intelligence for the volumetric quantification of brain structures on MRI in patients with neurological conditions. Focusing mainly on dementia and multiple sclerosis, she guides clinicians on how to make more evidence-based decisions and how icometrix can assist in this.
|Event Date||26.05.2021 6:00 pm CET|
|Event End Date||26.05.2021 7:00 pm CET|
|Registration Start Date||10.05.2021 11:00 pm|